苏州派瑞生物科技有限公司

Suzhou Pairui Biological Technology is a biopharmaceutical company dedicated to the discovery and development of innovative small molecule drugs through Targeted Protein Degradation (TPD). The company focuses on two primary technological pillars: Proteolysis Targeting Chimeras (PROTACs) and molecular glues, which are designed to degrade disease-causing proteins that are currently considered undruggable. By utilizing the body's natural ubiquitin-proteasome system, Pairui Biotech aims to provide novel therapeutic options for patients with cancer and autoimmune disorders. Headquartered in the Suzhou Industrial Park, the company is supported by venture capital from prominent Chinese investors like Oriza Seed. The leadership team consists of industry veterans with deep expertise in medicinal chemistry and early-stage drug discovery.